FDA Approves 3-in-1 Combination HIV Treatment


One-pill regiment includes abacavir, dolutegravir and lamivudine.

A new drug meant to treat patients with HIV-1 was recently approved.

A statement from ViiV Healthcare announced the approval by the US Food and Drug Administration (FDA) for the drug Triumeq (abacavir 600mg, dolutegravir 50mg, and lamivudine 300mg). The new drug allows for a one-pill regimen for HIV patients by combining the integrase strand transfer inhibitor dolutegravir with nucleoside reverse transcriptase inhibitors abacavir and lamivudine.

Approval for the new drug came following a Phase III study and a bioequivalence study which compared the medications being taken separately or in the single pill form. During the studies the most reported adverse reactions were insomnia, headache, and fatigue.

With the drug combining several medications the statement notes that it should not be taken by patients “with current or past history of resistance to any components of Triumeq.” It is also not recommended for patients “with resistance-associated integrase substitutions or clinically suspected INSTI resistance.”

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.